Beijing Huayuanchuang New Drug Research and Development

Beijing Huayuanchuang New Drug Research and Development is a clinical-stage biotechnology company based in Beijing, China, dedicated to the discovery of novel small molecule drugs. The company focuses on addressing unmet needs in oncology, particularly through the development of next-generation inhibitors for lung cancer and other solid tumors. Its lead candidate, HYC-001, is a fourth-generation EGFR inhibitor designed to overcome the C797S resistance mutation in non-small cell lung cancer. Beyond its lead program, the company is advancing a pipeline of inhibitors targeting KRAS and SOS1. Huayuanchuang leverages its internal medicinal chemistry expertise to develop precision medicines for patients with limited treatment options.